Publicaciones en colaboración con investigadores/as de Hospital Universitario 12 de Octubre (14)

2022

  1. Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial

    Breast, Vol. 66, pp. 77-84

2021

  1. Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

    Annals of Oncology, Vol. 32, Núm. 10, pp. 1245-1255

  2. Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study

    European Journal of Cancer, Vol. 156, pp. 70-82

2020

  1. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study

    Clinical and Translational Oncology, Vol. 22, Núm. 3, pp. 420-428

  2. Phase III study to evaluate patient’s preference of subcutaneous versus intravenous trastuzumab in HER2-positive metastatic breast cancer patients: Results from the ChangHER study (GEICAM/2012-07)

    European Journal of Cancer Care, Vol. 29, Núm. 4

2018

  1. Long-term response to first-line bevacizumab-based therapy in patients with metastatic breast cancer: Results of the observational “LORENA” study

    OncoTargets and Therapy, Vol. 11, pp. 5845-5852

  2. SEOM clinical guideline for treatment of cancer pain (2017)

    Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 97-107

2017

  1. New clinical trials regulation in Spain: analysis of royal decree 1090/2015

    Clinical and Translational Oncology, Vol. 19, Núm. 3, pp. 291-300

2016

  1. SEOM Clinical Guideline for bone metastases from solid tumours (2016)

    Clinical and Translational Oncology, Vol. 18, Núm. 12, pp. 1243-1253

2013

  1. Usefulness of the PERFORM questionnaire to measure fatigue in cancer patients with anemia: A prospective, observational study

    Supportive Care in Cancer, Vol. 21, Núm. 11, pp. 3039-3049

2011

  1. Psychometric properties of the Perform Questionnaire: A brief scale for assessing patient perceptions of fatigue in cancer

    Supportive Care in Cancer, Vol. 19, Núm. 5, pp. 657-666

2010

  1. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer

    Oncology, Vol. 79, Núm. 1-2, pp. 98-104

2009

  1. Development of a new questionnaire to assess patient perceptions of cancer-related fatigue: Item generation and item reduction

    Value in Health, Vol. 12, Núm. 1, pp. 130-138

  2. Nonpegylated liposomal doxorubicin (TLC-D99), Paclitaxel, and Trastuzumab in HER-2-overexpressing breast cancer: A multicenter phase l/ll study

    Clinical Cancer Research, Vol. 15, Núm. 1, pp. 307-314